Phase II/III, double-blind, placebo-controlled study of the use of BHV-8000 in participants with early-stage Parkinson's disease.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: BIOHAVEN PHARMACEUTICALS, INC.
- Phase: III
- Execution start: 27/10/2025
- End of execution: 30/03/2028
- PI: ADOLFO MINGUEZ CASTELLANOS
